Gabriel Olveira1, Casilda Olveira2, Esperanza Doña3, Francisco Javier Palenque4, Nuria Porras5, Antonio Dorado6, Ana M Godoy7, Elehazara Rubio-Martínez8, Gemma Rojo-Martínez9, Rocío Martín-Valero10. 1. UGC Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain; CIBERDEM, CIBER of Diabetes and Associated Metabolic Diseases (CB07/08/0019), Instituto de Salud Carlos III, Spain. Electronic address: gabrielm.olveira.sspa@juntadeandalucia.es. 2. UGC de Neumología, IBIMA (instituto de Biomedicina de Málaga), Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain, Avenida Carlos Haya, Málaga 29010, Spain. Electronic address: casi1547@separ.es. 3. Neumología, Hospital de Alta resolución de Benalmádena, Spain. Electronic address: esperuli@gmail.com. 4. UGC Rehabilitación, Hospital Regional Universitario de Málaga, Spain. Electronic address: fran_palenque@hotmail.com. 5. UGC Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain. Electronic address: nporrasperez@hotmail.com. 6. UGC de Neumología, IBIMA (instituto de Biomedicina de Málaga), Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain, Avenida Carlos Haya, Málaga 29010, Spain. Electronic address: antoniodoradog@gmail.com. 7. UGC Rehabilitación, Hospital Regional Universitario de Málaga, Spain. Electronic address: agrala@hotmail.com. 8. UGC Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain; CIBERDEM, CIBER of Diabetes and Associated Metabolic Diseases (CB07/08/0019), Instituto de Salud Carlos III, Spain. Electronic address: elehazara@gmail.com. 9. UGC Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain; CIBERDEM, CIBER of Diabetes and Associated Metabolic Diseases (CB07/08/0019), Instituto de Salud Carlos III, Spain. Electronic address: gemma.rojo.m@gmail.com. 10. Escuela Universitaria Francisco Maldonado de Osuna, Spain. Electronic address: rovalemas@gmail.com.
Abstract
BACKGROUND & AIMS:Pulmonary Rehabilitation (PR) is recommended for bronchiectasis but there is no data about its effect on body composition. The aim of this study is to assess the effect of Pulmonary Rehabilitation (PR) for 12 weeks in normally-nourished non-cystic-fibrosis bronchiectasis patients compared with the effect of PR plus a hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB) on body composition, muscle strength, quality of life and serum biomarkers. METHODS: single center randomized controlled trial, parallel treatment design: Participants were randomly assigned to receive PR for 12 weeks or PR plus ONS (PRONS) (one can per day). Outcome assessments were performed at baseline, 12 weeks and 24 weeks: body composition (Dual-energy X-Ray Absorptiometry (DEXA), mid-arm muscle circumference (MAMC), phase angle by Bio-impedance), health related quality of life (Spanish QOL-B-V3.0, Physical Functioning Scale), handgrip strength, diet questionnaire, and plasma levels of prealbumin, myostatin and somatomedin-c. RESULTS:Thirty patients were randomized (15 per group) without differences in clinical and respiratory variables. In the PRONS group bone mineral density (BMD), mean and maximum handgrip dynamometry, MAMC, QOLB and prealbumin were significantly increased from baseline at 12 and 24 weeks and Fat free Mass (FFM) and FFM index, at 12 weeks. In the PR group only mean handgrip dynamometry and prealbumin were significantly increased at 12 and 24 weeks. In both groups plasma myostatin was reduced at 12 weeks (without significant differences). CONCLUSION: The addition of a hyperproteic ONS enriched with HMB to Pulmonary Rehabilitation could improve body composition, BMD, muscle strength and health related quality of life in bronchiectasis patients. Clinical Trials Number NCT02048397.
RCT Entities:
BACKGROUND & AIMS: Pulmonary Rehabilitation (PR) is recommended for bronchiectasis but there is no data about its effect on body composition. The aim of this study is to assess the effect of Pulmonary Rehabilitation (PR) for 12 weeks in normally-nourished non-cystic-fibrosis bronchiectasispatients compared with the effect of PR plus a hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB) on body composition, muscle strength, quality of life and serum biomarkers. METHODS: single center randomized controlled trial, parallel treatment design: Participants were randomly assigned to receive PR for 12 weeks or PR plus ONS (PRONS) (one can per day). Outcome assessments were performed at baseline, 12 weeks and 24 weeks: body composition (Dual-energy X-Ray Absorptiometry (DEXA), mid-arm muscle circumference (MAMC), phase angle by Bio-impedance), health related quality of life (Spanish QOL-B-V3.0, Physical Functioning Scale), handgrip strength, diet questionnaire, and plasma levels of prealbumin, myostatin and somatomedin-c. RESULTS: Thirty patients were randomized (15 per group) without differences in clinical and respiratory variables. In the PRONS group bone mineral density (BMD), mean and maximum handgrip dynamometry, MAMC, QOLB and prealbumin were significantly increased from baseline at 12 and 24 weeks and Fat free Mass (FFM) and FFM index, at 12 weeks. In the PR group only mean handgrip dynamometry and prealbumin were significantly increased at 12 and 24 weeks. In both groups plasma myostatin was reduced at 12 weeks (without significant differences). CONCLUSION: The addition of a hyperproteic ONS enriched with HMB to Pulmonary Rehabilitation could improve body composition, BMD, muscle strength and health related quality of life in bronchiectasispatients. Clinical Trials Number NCT02048397.
Authors: Mariëlle P K J Engelen; Renate Jonker; John J Thaden; Gabriella A M Ten Have; Moon Sun Jeon; Srinivasan Dasarathy; Nicolaas E P Deutz Journal: Clin Nutr Date: 2020-01-29 Impact factor: 7.324
Authors: Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti Journal: Ann Thorac Med Date: 2017 Jul-Sep Impact factor: 2.219
Authors: A Sanz-Paris; M Camprubi-Robles; J M Lopez-Pedrosa; S L Pereira; R Rueda; M D Ballesteros-Pomar; J M Garcia Almeida; A J Cruz-Jentoft Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075
Authors: V Contreras-Bolívar; G Olveira; N Porras; E Acosta; E Rubio-Martín; M J Tapia-Guerrero; J Abuin-Fernández; C Olveira Journal: Sci Rep Date: 2019-10-10 Impact factor: 4.379
Authors: Rocio Martín-Valero; Ana Maria Jimenez-Cebrian; Jose A Moral-Munoz; Maria de-la-Casa-Almeida; Manuel Rodriguez-Huguet; Maria Jesus Casuso-Holgado Journal: J Clin Med Date: 2020-01-15 Impact factor: 4.241